Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol

We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroi...

Full description

Bibliographic Details
Main Authors: D.L. Gregory, C.D. Jones, E.R.E. Denton, A.N. Harnett
Format: Article
Language:English
Published: SAGE Publishing 2008-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S339
id doaj-fe10617c02ef4b7caabe4bdffc4f77c3
record_format Article
spelling doaj-fe10617c02ef4b7caabe4bdffc4f77c32020-11-25T03:24:02ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492008-01-01210.4137/CMO.S339Acute Visual Loss Induced by Dexamethasone during Neoadjuvant DocetaxolD.L. Gregory0C.D. Jones1E.R.E. Denton2A.N. Harnett3Department of Oncology, Addenbrookes Hospital, Cambridge, UK.Department of Ophthalmology, Norfolk and Norwich University Hospital Norwich, UK.Department of Radiology, Norfolk and Norwich University Hospital Norwich, UK.Department of Oncology, Norfolk and Norwich University Hospital Norwich, UK.We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroids but has not been previously reported in association with the management of solid tumours. Reduction in steroid dose and duration permitted recovery of her visual acuity while allowing completion of the prescribed chemotherapy regimen. An overview of the presentation, pathogenesis, aetiologies and management of central serous retinopathy is given.https://doi.org/10.4137/CMO.S339
collection DOAJ
language English
format Article
sources DOAJ
author D.L. Gregory
C.D. Jones
E.R.E. Denton
A.N. Harnett
spellingShingle D.L. Gregory
C.D. Jones
E.R.E. Denton
A.N. Harnett
Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol
Clinical Medicine Insights: Oncology
author_facet D.L. Gregory
C.D. Jones
E.R.E. Denton
A.N. Harnett
author_sort D.L. Gregory
title Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol
title_short Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol
title_full Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol
title_fullStr Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol
title_full_unstemmed Acute Visual Loss Induced by Dexamethasone during Neoadjuvant Docetaxol
title_sort acute visual loss induced by dexamethasone during neoadjuvant docetaxol
publisher SAGE Publishing
series Clinical Medicine Insights: Oncology
issn 1179-5549
publishDate 2008-01-01
description We present a case of a female patient who developed acute onset of visual loss due to central serous retinopathy as a consequence of steroid premedication for docetaxol given as second line neoadjuvant chemotherapy for breast cancer. Central serous retinopathy is a recognised association with steroids but has not been previously reported in association with the management of solid tumours. Reduction in steroid dose and duration permitted recovery of her visual acuity while allowing completion of the prescribed chemotherapy regimen. An overview of the presentation, pathogenesis, aetiologies and management of central serous retinopathy is given.
url https://doi.org/10.4137/CMO.S339
work_keys_str_mv AT dlgregory acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol
AT cdjones acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol
AT eredenton acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol
AT anharnett acutevisuallossinducedbydexamethasoneduringneoadjuvantdocetaxol
_version_ 1724603772124004352